Eli Lilly has added to its early-stage diabetes pipeline by collaborating with KeyBioScience AG and gaining a worldwide licence to develop the Swiss company’s dual amylin calcitonin receptor agonists (DACRAs), a potential new class of treatments for metabolic disorders. Lilly has paid an initial payment of US$55 M to KeyBioScience and the latter is also entitled to milestone and royalty payments. The deal was driven by potential type 2 diabetes candidate, KBP-042, which is currently in Phase II development.